ErbB4, a member of the epidermal growth factor receptor family, plays a role in normal breast and breast cancer development by regulating mammary epithelial cell proliferation, survival and differentiation. In this study, we show that WWP1, a C2-WW-HECT type E3 ubiquitin ligase, binds, ubiquitinates and destructs ErbB4-CYT1, but much less efficiently for CYT2, isoforms (both JMa and JMb). The protein-protein interaction occurs primarily between the first and third WW domains of WWP1 and the second PY motif of ErbB4. Knockdown of WWP1 by two different small interfering RNAs increases the endogenous ErbB4 protein levels in both MCF7 and T47D breast cancer cell lines. In addition, overexpression of the wild type, but not the catalytic inactive WWP1, dramatically decreases the endogenous ErbB4 protein levels in MCF7. Importantly, we found that WWP1 negatively regulates the heregulin-b1-stimulated ErbB4 activity as measured by the serum response element report assay and the BRCA1 mRNA expression. After a systematic screening of all WWP1 family members by small interfering RNA, we found that AIP4/Itch and HECW1/NEDL1 also negatively regulate the ErbB4 protein expression in T47D. Interestingly, the protein expression levels of both WWP1 and ErbB4 are higher in estrogen receptor-a-positive than in estrogen receptor-anegative breast cancer cell lines. These data suggest that WWP1 and its family members suppress the ErbB4 expression and function in breast cancer.
Introduction
The WW domain containing E3 ubiquitin protein ligase 1 (WWP1) belongs to the C2-WW-HECT type E3 family, which comprises of nine members including AIP4/Itch and WWP1 (Chen and Matesic, 2007) . The N-terminal C2 domain is responsible for calciumdependent phospholipid binding. The middle four WW domains recognize substrates with PY (PPXY) motifs. The C-terminal HECT domain is the enzyme catalytic center for the ubiquitin transfer. WWP1 is overexpressed in prostate cancer (Chen et al., 2007a) and estrogen receptor-a (ER-a)-positive breast cancers and promotes breast cell proliferation and survival (Chen et al., 2007b (Chen et al., , 2009 Nguyen Huu et al., 2008) . WWP1 is an intrinsic E3 ubiquitin ligase for multiple PY motifs containing transcription factors, including Smad2 (Seo et al., 2004) , RunX2 (Jones et al., 2006) , KLF5 (Chen et al., 2005) and p63 (Li et al., 2008b) . In addition, WWP1 may indirectly regulate several receptors, including ER-a (Chen et al., 2009) , epidermal growth factor receptor (EGFR) and ErbB2 (Chen et al., 2008) .
The EGFR subfamily of receptor tyrosine kinases consists of four homologous members: EGFR, ErbB2, ErbB3 and ErbB4 (HER4). Unlike other ErbB family members, ErbB4 may have tumor-suppressor activities because ErbB4 decreases breast epithelial cell proliferation (Pitfield et al., 2006; Muraoka-Cook et al., 2006a; Feng et al., 2007) , and promotes differentiation (Muraoka-Cook et al., 2006b and apoptosis (Naresh et al., 2006; Vidal et al., 2007) . Consistently, many studies suggest that the ErbB4 expression correlates with a good prognosis in breast cancer (Kew et al., 2000; Witton et al., 2003; Barnes et al., 2005; Koutras et al., 2008) . However, inconsistent results have also been frequently reported (Tang et al., 1999; Junttila et al., 2005; Maatta et al., 2006; Zhu et al., 2006) . Nevertheless, ErbB4 seems not to be a strong tumor suppressor because ErbB4 knockout does not affect ErbB2-induced breast tumorigenesis (Jackson-Fisher et al., 2006) .
ErbB4 is a 180-kDa glycoprotein consisting of a ligand-binding extracellular region, a hydrophobic transmembrane region, and a cytoplasmic region including a tyrosine kinase domain and a cytoplasmic tail ( Figure 1a ). Alternative splicing of the ErbB4 transcripts generates four mRNA variants that differ in the sequence encoding the extracellular juxtamembrane region (JMa and JMb) and the cytoplasmic region (CYT-1 and CYT-2). The JMa isoforms, unlike the JMb isoforms, include a cleavage site for the tumor necrosis factor-a-converting enzyme (TACE) on ligand binding. ErbB4 first cleaved by TACE is a substrate for g-secretase that releases a soluble 80-kDa intracellular domain that can translocate into the nucleus and regulate gene transcription. The ErbB4-CYT1 isoforms contain a 16-amino acid peptide with a PY motif that can be recognized by WW domains (Omerovic et al., 2004) . There are two additional PY motifs in ErbB4-CYT1 isoforms (Figure 1a ). Several WW domains containing proteins, including WWOX (Aqeilan et al., 2005) , YAP (Komuro et al., 2003; Omerovic et al., 2004) and AIP4/Itch (Omerovic et al., 2007) , have been reported to bind to ErbB4 through these PY motifs.
As both WWP1 and ErbB4 play important roles in breast cancer, we hypothesize that WWP1 regulates the ErbB4 activity through the WW/PY motif interaction. Here, we show that WWP1 specifically interacts with and targets the ErbB4-CYT1 isoforms for ubiquitin-mediated degradation and modulates the ligand-dependent ErbB4 activity. These findings shed light on the mechanism of WWP1 action and may help design future breast cancer target therapy. Figure 1 The WWP1 protein interacts with ErbB4 proteins through the WW/PY motifs in mammalian cells. (a) Schematic diagram of ErbB4 isoforms. Alternative splicing generates four ErbB4 isoforms because of a difference at the juxtamembrane (JM) or cytoplasmic (CYT) domains. JMa isoforms, unlike JMb isoforms, include a cleavage site for tumor necrosis factor-a-converting enzyme (TACE), and can be cleaved by TACE, resulting in the shedding of the extracellular domain (ECD), which is a substrate of g-secretase that releases a soluble intracellular domain (ICD) from the cell membrane. CYT-1 isoforms, unlike CYT-2 isoforms, contain a 16-amino acid sequence that includes a PI3-K binding site (YTPM) as well as a proline-rich protein interaction motif (PPAY). (b) Both JMb-CYT1 and JMa-CYT1 are co-immunoprecipitated with Myc-WWP1C886S (Wm), and PY3 and PY1, 3 mutants also interact with WWP1. However, the PY2, 3 mutant of JMb-CYT1 and JMa-CYT2 (having no second PY motif isoform) cannot be coimmunoprecipitated with Myc-Wm. HEK293T cells were co-transfected with different combinations of expression plasmids for MycWm, JMb-CYT1 wild type (WT), PY3, PY1, 3, PY2, 3, JMa-CYT1 and JMa-CYT2. immunoprecipitation (IP) was carried out using anti-Myc antibody (Ab). Myc-Wm was probed by anti-WWP1 Ab. The catalytic inactive WWP1 mutant was used to avoid ErbB4 degradation by WT WWP1. b-actin serves as a loading control for the input. (c) WWP1 binds to ErbB4-JMa-CYT1 through the first and third WW domains, as determined by glutathione S-transferase (GST) pull-down assays. Four WW domains of WWP1 were individually or collectively expressed as GST fusion proteins in the HEK293T cells. (d) The endogenous WWP1 protein forms a complex with the endogenous ErbB4 (JMa-CYT1) protein in MCF7. The ErbB4 protein was probed with the rabbit anti-ErbB4 Ab. The same amount of rabbit IgG nonspecifically immunoprecipitated few WWP1 after extensive washing. However, anti-ErbB4 Ab immunoprecipitated much more WWP1 than the IgG control under the same conditions.
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Results
WWP1
interacts with ErbB4 mainly through the first and third WW domains of WWP1 and the second PY motif of ErbB4 The ErbB4 protein has been shown to interact with several WW domains containing proteins, such as Itch, WWOX and YAP, through the WW/PY motif interaction (Aqeilan et al., 2005; Omerovic et al., 2007) . To test whether WWP1 also interacts with ErbB4, we first carried out the co-immunoprecipitation (IP) experiments. A plasmid expressing Myc-WWP1C886S (a catalytic inactive mouse WWP1 mutant) and plasmids expressing ErbB4 (different isoforms) were transfected into HEK293T cells. Myc-WWP1C886S was efficiently immunoprecipitated by the anti-Myc antibody (Ab) (Figure 1b) . We found that both JMa-CYT1 and JMb-CYT1 isoforms are co-immunoprecipitated with Myc-WWP1C886S. The anti-Myc Ab itself cannot immunoprecipitate the ErbB4 proteins without the expression of Myc-WWP1C886S, suggesting that the protein-protein interactions are specific.
Then we tested whether the protein-protein interaction between WWP1 and ErbB4 is through the WW/PY motifs and which PY motif is involved in the interaction. We mutated the PY motifs in ErbB4-JMb CYT1 (PY1, PY1, 3 and PY2, 3) by substituting tyrosine (Y) with phenylalanine (F). We found that ErbB4-JMb CYT1-PY3 and -PY1, 3 mutants still interact with Myc-WWP1C886S; however, the ErbB4-JMb CYT1-PY2, 3 mutants almost completely loses the interaction with Myc-WWP1C886S (Figure 1b) . A similar result was observed for the ErbB4-JMa isoform. The ErbB4-JMa-CYT2, which does not have the second PY motif, almost never interacts with Myc-WWP1C886S at all (Figure 1b) . These results suggest that the second PY motif in ErbB4-CYT1 is essential for WWP1 interaction and the CYT2 isoforms do not interact with WWP1 efficiently in spite of the existence of two other PY motifs.
Then, we asked which WW domain of WWP1 participates in the protein interaction with ErbB4. We fused each of the four WW domains of WWP1 to the Cterminus of glutathione S-transferase (GST) and carried out GST pull-down assays with ErbB4-JMa-CYT1 in HEK293T cells. As shown in Figure 1c , GST itself does not pull down any ErbB4. All four GST-WW proteins pull down different amounts of ErbB4. GST-WW1 and GST-WW3 pull down a similar and large amount of ErbB4, whereas GST-WW2 and GST-WW4 pull down much less ErbB4, although the expression levels of GST-WW and ErbB4 are similar in the four different groups. Consistently, GST-WW (1-2), GST-WW (3-4) and GST-WW (1-4) efficiently pull down ErbB4. It seems that more WW domains bind to more ErbB4. These findings suggest that the first and third WW domains play major roles for ErbB4 binding and the second and fourth WW domains also contribute to recognizing ErbB4. Taken together, the protein interaction between WWP1 and ErbB4 is primarily through the first and third WW domains of WWP1.
Finally, we examined whether the endogenous WWP1 protein interacts with the endogenous ErbB4 protein. The ErbB4 (JMa-CYT1 (Maatta et al., 2006) ) proteins were immunoprecipitated from MCF7 by using the antiErbB4 Ab, and the endogenous WWP1 protein was detected in the same complex (Figure 1d ). This result suggests that the protein-protein interaction between WWP1 and ErbB4 occurs at the physiological level.
WWP1 ubiquitinates ErbB4 in cultured mammalian cells As the WWP1 E3 ligase interacts with both ErbB4-CYT1 isoforms, we asked whether WWP1 ubiquitinates the ErbB4-CYT1 proteins in mammalian cells. To this end, we transfected the expression constructs for wildtype (WT) human WWP1, the catalytic inactive hWWP1C890A mutant, ErbB4, and Myc-Ub into HEK293T cells. We carried out IP with the anti-ErbB4 Ab together with protein A/G agarose beads under a denaturing condition to eliminate any ErbB4-associated proteins through non-covalent bonds. The ubiquitinconjugated ErbB4 proteins were detected by western blot with anti-Myc Ab. As shown in Figure 2a , WT, but not the catalytic inactive WWP1, significantly increases the ubiquitination of ErbB4-CYT1 (both JMa and JMb) compared with the vector control. The format of ErbB4 ubiquitination by WWP1 is most likely polyubiquitination because a smear of bands above the unmodified ErbB4 was detected. These results indicate that WWP1 polyubiquitinates ErbB4-CYT1 isoforms through its E3 ligase activity.
As WWP1 does not interact with ErbB4 isoforms without the second PY motif, we examined the ubiquitination of the ErbB4-JMb-CYT1-PY3, -PY1, 3 and -PY2, 3 and -JMa-CYT2 by WWP1. Consistent with the protein interaction results, WWP1 less efficiently ubiquitinates ErbB4-JMb-CYT1-PY3 and -PY1, 3 isoforms but barely ubiquitinates the ErbB4-JMb-CYT1-PY2, 3 and ErbB4-JMa-CYT2 isoforms under the same conditions. We conclude that the protein interaction is essential for WWP1 to ubiquitinate ErbB4.
To investigate whether endogenous WWP1 contributes to the endogenous ErbB4 ubiquitination, we knocked down WWP1 in T47D by an anti-WWP1 small interfering RNA (siRNA) and examined the ubiquitination of ErbB4 (JMa-CYT1 (Maatta et al., 2006) ). Compared with the Luc siRNA, the anti-WWP1 siRNA efficiently silences the WWP1 protein expression and decreases the ubiquitinated ErbB4 (Figure 2b ).
WWP1 promotes ErbB4 protein degradation
To test whether WWP1 promotes ErbB4 protein degradation, we first measured the steady-state levels of ErbB4-CYT1 in the presence and absence of WWP1. As shown in Figure 3a , the steady-state levels of ErbB4-CYT1 (both JMa and JMb isoforms) are dramatically decreased in WT WWP1 but not in the WWP1C890A overexpressing HEK293T cells. As expected, WT WWP1 fails to dramatically decrease the steady-state level of ErbB4-JMa-CYT2 ( Figure 3a ) compared with WWP1C890A because JMa-CYT2 cannot interact with WWP1 nor be ubiquitinated by WWP1. In addition, we found that WT WWP1, but not WWP1C890A, decreases the steady-state levels of ErbB4-JMa-CYT1 in a dosage-dependent manner ( Figure 3b ). We did observe that a high level of WWP1 or WWP1C890A can slightly decrease the ErbB4-JMa-CYT2 protein levels by an unknown reason (Figures 3a and b) .
To further investigate whether the decrease of ErbB4 by WWP1 is because of the increase of protein degradation, we measured the half-lives of ErbB4 isoforms in the presence and absence of WWP1 by cycloheximide chase assays. As shown in Figures 3c and d, all tested ErbB4 isoforms (CYT1 and CYT2) show a long half-life (>10 h) in HEK293T cells. When WT WWP1 is co-expressed, the half-lives of ErbB4-CYT1 isoforms are dramatically decreased to about 2 h (Figures 3c and d) . The catalytic inactive WWP1C890A does not significantly affect the half-life of ErbB4-CYT1 isoforms. Consistent with the results that WWP1 ubiquitinates the ErbB4-JMb-CYT1-PY3 and -PY1, 3 isoforms with reduced efficiencies, WWP1 decreases the half-lives of these mutants less efficiently (B3.5 h for PY3 and B4 h for PY1, 3). In addition, ErbB4-JMb-CYT1-PY2, 3 and ErbB4-JMa-CYT2 isoforms are resistant to WWP1-mediated degradation (Figures 3c  and d ) because of the lack of protein ubiquitination by WWP1.
To further characterize the mechanism by which ErbB4 is degraded after ubiquitination by WWP1, we carried out cycloheximide chase assays in the presence of the proteasome inhibitor, MG132, and the lysosome inhibitor, chloroquine. As shown in Figures 3c and d , WWP1-induced ErbB4 degradation is partly blocked by MG132, but not chloroquine, suggesting that the degradation of ErbB4 by WWP1 is partly through the 26S proteasome, not by the lysosome.
WWP1 downregulates the endogenous ErbB4 protein levels in breast cancer cells
To determine whether WWP1 targets ErbB4 for degradation under physiological conditions, we knocked down endogenous WWP1 by two different anti-WWP1 siRNAs in two breast cancer cell lines, T47D and MCF7, expressing ErbB4-JMa-CYT1 (Maatta et al., 2006) . We found that the endogenous ErbB4 protein levels are remarkably elevated in both cell lines when WWP1 is knocked down by both siRNAs (Figure 4a ). The ErbB4 mRNA levels are not changed by WWP1 knockdown in these cells (data not shown). These results suggest that WWP1 targets the endogenous ErbB4 protein for degradation in breast cancer cell lines.
In addition, we stably overexpressed WWP1 and WWP1C890A in MCF7. The expression of WT and mutant WWP1 in MCF7 populations was shown by western blotting (Figure 4b ). We found that WT WWP1 dramatically decreases the endogenous ErbB4 protein level compared with LacZ and WWP1C890A (Figure 4b ). For an unknown reason, WWP1C890A also decreases the ErbB4 protein level compared with LacZ. To exclude the possibility that the regulation is at the mRNA level, we examined the ErbB4 mRNA levels ubiquitinates both juxtamembrane (JM)a-cytoplasmic (CYT)1 and JMb-CYT1 isoforms using its E3 ligase activity. WWP1 also ubiquitinates the PY3 and PY1, 3 mutants of JMb-CYT1 with reduced efficiency, but it cannot efficiently ubiquitinate the PY2, 3 mutant of JMb-CYT1 and JMa-CYT2 isoforms. HEK293T cells were co-transfected with expressing plasmids for Myc-Ub, WWP1, WWP1C890A, JMa-CYT1, JMa-CYT2 and JMb-CYT1 (wild type (WT), PY3, PY1, 3 and PY2, 3 mutants) as indicated. The cells were treated with 20 mM of the proteasome inhibitor, MG132, overnight to accumulate the ubiquitinated ErbB4 species. The immunoprecipitation (IP) was carried out with the anti-ErbB4 antibody (Ab) with protein A/G beads under denaturing conditions. Immunoblotting was carried out with the indicated Abs. The ubiquitinconjugated ErbB4 proteins were detected by anti-Myc Ab. (b) The endogenous WWP1 E3 ligase ubiquitinates the endogenous ErbB4 protein in T47D. WWP1 was knocked down by anti-WWP1 siRNA#1 (Wsi). The anti-luciferase small interfering RNA (siRNA) (Lsi) was used as the negative control. MG132 was added to the cells for overnight. IP was carried out under a denaturing condition using anti-ErbB4 Ab. The ubiquitin-conjugated ErbB4 proteins were detected by anti-Ub Ab. Wild-type (WT) WWP1, but not WWP1C890A, overexpression dramatically decreases the endogenous ErbB4 protein expression in MCF7. WT and mutant WWP1C890A were transduced into MCF7 by a lentiviral system. LacZ was used as the negative control. The blasticidin (10 mg/ml)-resistant cell populations were used for western blot. The WWP1C890A mutant also slightly decreases the ErbB4 levels in MCF7 for an unknown reason. (c) Measurement of endogenous ErbB4 half-lives by cycloheximide (CHX) chase assays. WWP1 was knocked down in T47D by anti-WWP1 siRNA #1 (Wsi) and the control siRNA (Lsi) for 2 days. The cells were incubated with 50 mg/ml CHX for different times (2-4 h) and were harvested for western blotting. b-actin was used as a loading control. (d) Quantative results of ErbB4 degradation from panel c by IMAGE J software. (e) MCF7 cells were transfected with the serum response element (SRE)-Luc plasmid together with luciferase (L), WWP1 (W) and ErbB4 (E) siRNAs. Twenty-four hours later, the transfected cells were serum-starved overnight and were stimulated with heregulin (HRG)-b-1 (100 ng/ml) for 8 h. Cell lysates from three parallel wells were pooled, and equal amounts of proteins were subjected to immunoblotting for ErbB4 and WWP1. (f) WWP1 regulates the SRE promoter activity through ErbB4. The average relative luciferase activities are plotted. WWP1 siRNA significantly increases the HRG-b-1-induced SRE promoter activity in MCF7, whereas ErbB4 siRNA significantly decreases the HRG-b-1-induced SRE promoter activity in MCF7. Knockdown of ErbB4 can partially rescue WWP1 siRNA-induced SRE promoter activity. All statistics were analysed by a t-test. **Po0.01. (g) Knockdown of ErbB4 can partially rescue WWP1 siRNA-induced BRCA1 mRNA expression in the presence of HRG-b-1 (100 ng/ml) in MCF7. The normalized BRCA1 mRNA levels were labeled below each lane. Overexpression of WT WWP1 and WWP1C890A decreases BRCA1 mRNA levels in the presence of HRG-b-1 (100 ng/ml) in MCF7. (Figures 4c and d) .
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WWP1 inhibits the ErbB4 biological activities in breast cancer
As a receptor tyrosine kinase, ErbB4 initiates signaling on binding to ligands such as heparin-binding EGF-like WWP1 targets ErbB4 for degradation Y Li et al growth factor, betacellulin, epiregulin and heregulin (HRG) (Sundvall et al., 2008) . It has been reported that HRG can activate the serum response element (SRE) through ErbB4 (Omerovic et al., 2007) . To investigate whether WWP1 inhibits the ErbB4 downstream signaling, we measured the ErbB4 activities using the SRE luciferase reporter assay after knocking down WWP1 and ErbB4 in MCF7. The knockdown effect of WWP1 and ErbB4 is shown in Figure 4e . As expected, knockdown of WWP1 increases the ErbB4 expression levels in the absence and presence of HRG-b-1. In contrast, knockdown of ErbB4 has no effect on the WWP1 expression. Another anti-ErbB4 siRNA has the same result (data not shown). As shown in Figure 4f , the ErbB4 activity is dramatically increased after HRG-b-1 stimulation. WWP1 knockdown significantly increases but ErbB4 knockdown significantly decreases the ErbB4 activity. Importantly, knockdown of ErbB4 can partially rescue the WWP1 siRNA-induced ErbB4 activity increase. These results suggest that WWP1 functions partially through ErbB4 in MCF7.
In addition, HRG-activated ErbB4 has been shown to increase the BRCA1 expression in MCF7 (MuraokaCook et al., 2006a). We examined the HRG-b-1-induced BRCA1 mRNA expression by reverse transcriptase-PCR. As shown in Figure 4g , ErbB4 siRNA decreases the BRCA1 mRNA levels by B20% but WWP1 siRNA increases the BRCA1 mRNA levels by B30%. When we combined both siRNAs, the BRCA1 mRNA level is similar to the control. Consistently, overexpression of WWP1, but not WWP1C890A, decreases the BRCA1 mRNA levels by B30%. These results suggest that the WWP1 knockdown-induced BRCA1 increase is indeed through ErbB4.
Itch and HECW1 also inhibit ErbB4 in breast cancer cell lines
It has been reported that the WWP1 family member, Itch, also targets ErbB4 for degradation in T47D (Omerovic et al., 2007) . To test whether the other WWP1 family members also regulate endogenous ErbB4 in breast cancer cells, we knocked down the other eight WWP1 family members by three different siRNAs for each gene in both T47D and MCF7. We found that siRNAs against Itch and HECW1 significantly increase the ErbB4 protein expression in T47D, but not in MCF7 (Figure 5a ), although all siRNAs against Itch and HECW1 work well in both cell lines (Figure 5b ). We also examined the knockdown efficiencies for several other E3 ligases and found that all siRNAs work well as expected (data not shown). We further compared the mRNA expression of eight E3 ligases in MCF7 and T47D by reverse transcriptase-PCR. As shown in Figure 5c , the Itch and HECW1 mRNA levels are higher in T47D than those in MCF7. These results may explain why knockdown of Itch and HECW1 increase the ErbB4 protein levels in T47D but not in MCF7. Finally, we found that knockdown of WWP1, Itch and HECW1 additively increase the endogenous ErbB4 protein levels in T47D although WWP1 and Itch are similarly more potent than HECW1 (Figure 5d ). These results suggest that Itch and HECW1 also negatively regulate the ErbB4 expression in breast cancer.
The expression of WWP1 and ErbB4 in breast cancer cell lines As WWP1 negatively regulates the ErbB4 protein stability in breast cancer cell lines, we examined the WWP1 and ErbB4 protein levels in a panel of eight breast cancer cell lines and expected to detect a negative correlation. As shown in Figure 5e , the full-length ErbB4 can only be detected in four ER-a-positive breast cancer cell lines (BT474, MCF7, T47D and HCC1500). Interestingly, WWP1 is also highly expressed in three out of four ER-positive breast cancer cell lines (BT474, MCF7 and HCC1500). These results are consistent with our previous reports (Chen et al., 2007b (Chen et al., , 2009 ). Both ErbB4 and WWP1 are lowly expressed in ER-a-negative breast cancer cell lines (MDA-MB-231, MDA-MB-468, HCC1937 and Hs578T). Thus, there is no negative correlation between the WWP1 protein expression and the ErbB4 protein expression in these breast cancer cell lines.
Discussion
In this study, we provide several lines of evidence to support that WWP1 targets the full-length ErbB4-CYT1 isoforms for ubiquitin-mediated degradation. First, WWP1 binds to ErbB4-CYT1 proteins through the WW/PY motif interaction. Second, WWP1 ubiquitinates ErbB4-CYT1 proteins through its E3 ubiquitin ligase activity. Third, WWP1 decreases the protein halflives of ErbB4-CYT1 proteins. Most importantly, endogenous WWP1 suppresses the endogenous ErbB4 protein levels and activities in breast cancer.
ErbB4 has been reported to be targeted for degradation by several E3 ligases, including Itch (Omerovic et al., 2007) , anaphase-promoting complex/cyclosome (Strunk et al., 2007) , and most recently WWP1 (Feng et al., 2009 ). While our study was ongoing, Feng et al. (2009) published that WWP1 selectively targets HER4/ ErbB4-JMa-CYT1 and its cleaved m80 for degradation. Although our research results completely support the conclusion that WWP1 targets the full-length ErbB4/ HER4 for degradation by using different strategies, there are several new discoveries in our study. First, we identified that the first and third WW domains of WWP1 play major roles for protein interaction. Second, we showed that WWP1 regulates both JMa and JMb isoforms. Most importantly, we examined all WWP1 family members by the RNA interference approach in two breast cancer cell lines and discovered that HECW1 may also suppress ErbB4 in breast cancer. In addition, we found that there is no negative correlation between the expression of WWP1 and ErbB4 in eight breast cancer cell lines. Finally, we found that ErbB4 does not regulate the endogenous WWP1 expression in breast cancer (Figure 4e ). This is different from the published results that ErbB4 decreases the WWP1 expression (Feng et al., 2009) .
We found that WWP1 specifically targets ErbB4-CYT1 but not CYT2 isoforms. Maatta et al. (2006) reported that JMa-CYT1, but not JMA-CYT2, is localized to early endosomes. WWP1 is also localized to endosomes (Chen et al., 2008) . However, the proteasome inhibitor, MG132, but not the lysosome inhibitor, chloroquine, partially block the WWP1-mediated ErbB4-CYT1 degradation (Figure 3) . Interestingly, the combination of MG132 and chloroquine synergistically blocks the WWP1-mediated ErbB4-CYT1 degradation (data not shown). Similar results have been observed by Feng et al. (2009) . The degradation mechanism of the ubiquitinated ErbB4 proteins remains to be elucidated.
Although transient WWP1 overexpression does not change the exogenous EGFR, ErbB2 and ErbB3 protein levels in COS7 cells (Feng et al., 2009) , we previously found that WWP1 upregulates EGFR and ErbB2 in MCF10A and PC-3 (Chen et al., 2008) . As EGFR and ErbB2 do not have a PY motif, the regulation of EGFR and ErbB2 by WWP1 is indirectly mediated through RNF11 (Chen et al., 2008) and may be cell line specific. In contrast, the direct regulation of ErbB4 by WWP1 is broadly detected in multiple cell lines.
One of the primary functions of ErbB4 in vivo is in the maturation of mammary glands during pregnancy and WWP1 targets ErbB4 for degradation Y Li et al lactation induction (Long et al., 2003; Tidcombe et al., 2003) . ErbB4 can activate the expression of the tumor suppressor gene, BRCA1, (Muraoka-Cook et al., 2006a) and differentiation genes such as b-casein (Muraoka-Cook et al., 2008) . Most studies suggest that ErbB4 also decreases breast epithelial cell proliferation (Pitfield et al., 2006; Muraoka-Cook et al., 2006a; Feng et al., 2007) and survival (Naresh et al., 2006; Vidal et al., 2007) . As an ErbB4-negative regulator, WWP1 has been shown to promote breast epithelial cell proliferation and survival (Chen et al., 2007b (Chen et al., , 2009 Nguyen Huu et al., 2008) . Whether WWP1 regulates mammary gland development during pregnancy and lactation through suppressing ErbB4 in vivo remains to be elucidated by studying the breast-specific WWP1 knockout and WWP1 transgenic mice in the future.
It is surprising that the expression of ErbB4 and WWP1 is not negatively correlated in breast cancer cell lines. Three ER-positive cell lines with ErbB4 expression (BT474, MCF7 and HCC1500) also show higher levels of WWP1 compared with four ER-negative breast cancer cell lines (Figure 5e ). The WWP1 protein expression has been associated with positive ER-a and good-prognosis breast tumors (Nguyen Huu et al., 2008; Chen et al., 2009) . Consistently, most publications associated the ErbB4 protein expression with ER-a-positive, low grade and more differentiated breast tumors (Tang et al., 1999; Suo et al., 2001; Witton et al., 2003; Junttila et al., 2005) . However, knockdown of endogenous WWP1 significantly upregulates endogenous ErbB4 protein expression in both T47D and MCF7 (Figure 4a ). It is becoming evident that the expression of ErbB4 is dynamically controlled by synthesis and degradation, which may explain the observation that both WWP1 and ErbB4 are co-expressed in the same breast cancer cells.
Besides WWP1, another WWP1 family member, Itch, has been reported to target ErbB4 for ubiquitinmediated degradation (Omerovic et al., 2007) . We confirmed that knockdown of Itch can upregulate ErbB4 in T47D but not in MCF7 ( Figure 5 ). It is partially because Itch is lowly expressed in MCF7. Similar results were observed for HECW1. HECW1 (NEDL1) has been shown to be an E3 ligase for Dvl-1 (Miyazaki et al., 2004) and to cooperate with p53 to induce apoptosis independent of its E3 ligase activity (Li et al., 2008a) . Thus, WWP1, Itch and HECW1 additively suppress the ErbB4 expression in some breast cancers.
In summary, we show that WWP1 specifically targets the ErbB4-CYT1 proteins for ubiquitin-mediated degradation and regulates its biological activities in breast cancer. Given the frequent gene amplification and overexpression of WWP1 in prostate and breast cancer, this knowledge may help us understand the role of WWP1 in prostate and breast cancer development and may be useful for guiding the development of anti-WWP1 and pan-ErbB kinase inhibitors for future prostate and breast cancer target therapy.
Materials and methods
Cell culture and transfection
The human embryonic kidney 293T (HEK293T) cell line was cultured in Dulbecco's modified Eagle's medium (DMEM) containing 5% fetal bovine serum (FBS) and 1% penicillin and streptomycin (PS). MCF7 breast cancer cells were grown in DMEM supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acid, 1.5 g/l sodium bicarbonate, 0.01 mg/ml insulin, 5% FBS and 1% PS. T47D breast cancer cells were cultured in RPMI 1640 medium with 2 mM L-glutamine and supplemented with 1 mM sodium pyruvate, 4.5 g/l glucose, 10 mM HEPES, 1.5 g/l sodium bicarbonate, 5% FBS, 0.01 mg/ml insulin and 1% PS.
All transient transfections for plasmids and siRNAs were carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Two chemically synthesized WWP1 siRNAs were purchased from Dharmacon (Chicago, IL, USA) and transfected at 100 nM final concentration. The siRNA target sequences for human WWP1 gene are 5 0 -GAAGTCATCTGT AACTAAA-3 0 (Wsi#1) and 5 0 -GCAGAGAAATACTGTTT AT-3 0 (Wsi#2). The 3 0 -UU overhang for both strands and 5 0 -phophorylation for antisense sequence were used for these siRNAs. The silencer select pre-designed siRNAs for ErbB4 and eight WWP1 family members were purchased from Applied Biosystems (Ambion, Austin, TX, USA). The target sequences for ErbB4 siRNAs are 5 0 -CCCTTACAATGCAAT TGAATT-3 0 and 5 0 -CCCGTAATGTCTTAGTGAATT-3 0 . The final concentration for silencer select siRNAs was 10 nM.
Expression plasmids
The plasmids expressing WT WWP1, the catalytic inactive hWWP1C890A, mWWP1C886S, and Myc-Ub have been described in our previous studies (Chen et al., 2005 (Chen et al., , 2007b . The ErbB4-JMa-CYT1, JMa-CYT2, JMb-CYT1, JMb-CYT1-PY3 mutant and pSRE-Luc constructs have been described in a previous study (Omerovic et al., 2007) . The first and second PY motifs were mutated based on the JMb-CYT1-PY3 mutant using a QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The resulting constructs express ErbB4-JMb-CYT1-PY1, 3 and ErbB4-JMb-CYT1-PY2, 3.
Antibodies
The anti-WWP1 rabbit polyclonal Ab has been described in our previous report (Chen et al., 2007a) . The anti-WWP1 mouse monoclonal Ab (1A7) is from Novus Biologicals, Inc (Littleton, CO, USA). The anti-b-actin mouse monoclonal Ab AC-15 (#A5441) is from Sigma (St Louis, MO, USA). The anti-Myc mouse monoclonal Ab 9B11 (#2276) is from Cell Signaling (Danvers, MA, USA). The anti-ErbB4 rabbit polyclonal Ab (C-18, #Sc-283), anti-ER-a Ab (H-184, #Sc-7207), anti-Ub Ab (#Sc-8017) and the rabbit IgG (#Sc-2027) are from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Immunoprecipitation and GST pull-down Immunoprecipitation using an anti-Myc Ab plus protein A-agarose beads and GST pull-down experiments have been described in our previous studies (Chen et al., 2005; Li et al., 2008b) . The anti-ErbB4 rabbit polyclonal Ab was used to immunoprecipitate the endogenous ErbB4 proteins from MCF7. The rabbit IgG was used as the negative control. The beads were washed five times with 500 ml of 1Â cell lysis buffer. Proteins were resuspended with 30 ml of SDS sample loading buffer and analysed by western blot.
Protein ubiquitination assay HEK293T cells were transiently transfected with Myc-Ub and other plasmids as necessary in 6-well plates. Two days after transfection, the cells were harvested in 150 ml SDS lysis buffer (50 mM Tris-Cl, pH 6.8, 1.5% SDS). The samples were boiled for 15 min. One hundred ml of protein lysate was diluted with 1.2 ml EBC/bovine serum albumin (BSA) buffer (50 mM TrisCl, pH 6.8, 180 mM NaCl, 0.5% CA630, 0.5% BSA) and incubated with 30 ml 50% anti-ErbB4 Ab together with protein A/G Plus-Agarose (#Sc-2003, Santa Cruz Biotechnology) overnight at 4 1C with rotation. The beads were collected by centrifugation at 10 000 g for 30 s at 4 1C and washed three times with 1 ml ice-cold EBC/BSA buffer. Proteins were resuspended with 30 ml of SDS sample loading buffer and analysed by western blot. Ubiquitin-conjugated ErbB4 was detected by anti-Myc Ab or anti-Ub Ab.
Luciferase reporter assay MCF7 cells were transfected with the SRE-luciferase reporter and the indicated combinations of WWP1 siRNA#1 and ErbB4 siRNA#1. At 8 h after transfection, the cells were starved overnight (16 h) and stimulated with 100 ng/ml of HRG-b1 (Sigma) for 8 h. Luciferase activities were measured by using the luciferase reporter assay system with a GloMax 20/20 Luminometer (Promega, Madison, WI, USA).
Reverse transcriptase-PCR Total RNA was extracted from the MCF7 and T47D cells using the Trizol reagent (Invitrogen). The cDNA was prepared by using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The primers used in this study are shown in Table 1 . 
